title: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
abstract: Caspofungin, a glucan synthesis inhibitor, is being developed as a parenteral antifungal agent. The pharmacokinetics of caspofungin following 1-h intravenous infusions in healthy men was investigated in four phase I studies. In an alternating two-panel (six men each), rising-single-dose study, plasma drug concentrations increased proportionally with the dose following infusions of 5 to 100 mg. The beta-phase half-life was 9 to 10 h. The plasma drug clearance rate averaged 10 to 12 ml/min. Renal clearance of unchanged drug was a minor pathway of elimination (approximately 2% of the dose). Multiple-dose pharmacokinetics were investigated in a 2-week, serial-panel (5 or 6 men per panel) study of doses of 15, 35, and 70 mg administered daily; a 3-week, single-panel (10 men) study of a dose of 70 mg administered daily; and a parallel panel study (8 men) of a dose of 50 mg administered daily with or without a 70-mg loading dose on day 1. Moderate accumulation was observed with daily dosing. The degree of drug accumulation and the time to steady state were somewhat dose dependent. Accumulation averaged 24% at 15 mg daily and approximately 50% at 50 and 70 mg daily. Mean plasma drug concentrations were maintained above 1.0 microg/ml, a target selected to exceed the MIC at which 90% of the isolates of the most clinically relevant species of Candida were inhibited, throughout therapy with daily treatments of 70 or 50 mg plus the loading dose, while they fell below the target for the first 2 days of a daily treatment of 50 mg without the loading dose. Caspofungin infused intravenously as a single dose or as multiple doses was generally well tolerated. In conclusion, the pharmacokinetics of caspofungin supports the clinical evaluation of once-daily dosing regimens for efficacy against fungal infections.
authors.affiliation: Merck Research Laboratories, West Point, Pennsylvania 19486, USA. julie_stone@merck.com
authors.forename: Julie A
authors.initials: JA
authors.lastname: Stone
authors.forename: Sherry D
authors.initials: SD
authors.lastname: Holland
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Wickersham
authors.forename: Andrew
authors.initials: A
authors.lastname: Sterrett
authors.forename: Michael
authors.initials: M
authors.lastname: Schwartz
authors.forename: Cynthia
authors.initials: C
authors.lastname: Bonfiglio
authors.forename: Michael
authors.initials: M
authors.lastname: Hesney
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Winchell
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Deutsch
authors.forename: Howard
authors.initials: H
authors.lastname: Greenberg
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Hunt
authors.forename: Scott A
authors.initials: SA
authors.lastname: Waldman
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D000077336:Caspofungin; D004311:Double-Blind Method; D054714:Echinocandins; D006801:Humans; D007262:Infusions, Intravenous; D055666:Lipopeptides; D008297:Male; D010455:Peptides; D010456:Peptides, Cyclic
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin